Oncopeptides

Oncopeptides reported net sales of SEK 31.1m in Q2 2026, up 62% year‑on‑year, and SEK 56.5m in the first half (+74%). Gross margin in H1 was 98%, the EBIT loss narrowed to SEK 86.2m, and operating costs fell slightly. The company reported SEK 158m in cash after a March rights issue and reiterated its target to reach positive cash flow in 2027. The share rose about 10% in early trading but remains well below the 52‑week high. » Więcej na de.investing.com

Oncopeptides reports Q3 2025 revenue of SEK 20.2m, up 174% year‑on‑year, and a gross margin of 99%. EBIT improved to -SEK 47.1m but remained negative, while operating expenses were slightly reduced. After an oversubscribed rights issue, liquidity stands at SEK 147.9m; the company aims for positive cash flow by the end of 2026. Oncopeptides is advancing commercialization in Europe (Germany, Spain, Italy) and is negotiating partnerships in Japan, but uncertainty over growth and timing failed to reassure investors, sending the stock down nearly 14%. » Więcej na de.investing.com

Oncopeptides reported Q3 2025 net revenue growth of 174% to SEK 20.2m and a gross profit of SEK 19.9m with a gross margin of 99%. Operating expenses fell 3% and EBIT improved from -SEK 61.3m to -SEK 47.1m; after a capital raise liquidity stands at SEK 147.9m. Despite the progress, the stock fell 12.44% in pre-market trading as investors voiced concerns about operational challenges, market expansion and the timeline to profitability by end-2026. Management plans to expand its market presence in Europe and will present further details at the capital markets day on 13 November. » Więcej na de.investing.com